Advertisement
Screener

ANI PHARMACEUTICALS, INC (ANIP) Increase (Decrease) in Other Operating Liabilities

2.8 / 5 stars · 68/120 Roast Me

ANI PHARMACEUTICALS, INC Increase (Decrease) in Other Operating Liabilities

ANI PHARMACEUTICALS, INC (ANIP) reported Increase (Decrease) in Other Operating Liabilities of $1.34 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-06.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2018-11-06

  • ANI PHARMACEUTICALS, INC increase (decrease) in other operating liabilities for the quarter ending 2018-09-30 was $1.02M, a 43.14% decline year-over-year.
  • ANI PHARMACEUTICALS, INC increase (decrease) in other operating liabilities for the quarter ending 2018-06-30 was -$749.00K.
  • ANI PHARMACEUTICALS, INC increase (decrease) in other operating liabilities for the quarter ending 2018-03-31 was $1.07M, a 7.92% decline year-over-year.
  • ANI PHARMACEUTICALS, INC increase (decrease) in other operating liabilities for the quarter ending 2017-12-31 was -$1.17M.
  • ANI PHARMACEUTICALS, INC increase (decrease) in other operating liabilities for fiscal 2017 was $644.00K, a 31.49% decline from fiscal 2016.
  • ANI PHARMACEUTICALS, INC increase (decrease) in other operating liabilities for fiscal 2016 was $940.00K, a 944.44% increase from fiscal 2015.
  • ANI PHARMACEUTICALS, INC increase (decrease) in other operating liabilities for fiscal 2015 was $90.00K, a 62.50% decline from fiscal 2014.
  • ANI PHARMACEUTICALS, INC increase (decrease) in other operating liabilities for fiscal 2014 was $240.00K.
Period endIncrease (Decrease) in Other Operating Liabilities 3 monthIncrease (Decrease) in Other Operating Liabilities 3 month as first filedIncrease (Decrease) in Other Operating Liabilities 6 monthIncrease (Decrease) in Other Operating Liabilities 6 month as first filedIncrease (Decrease) in Other Operating Liabilities 9 monthIncrease (Decrease) in Other Operating Liabilities 9 month as first filedIncrease (Decrease) in Other Operating Liabilities 12 monthIncrease (Decrease) in Other Operating Liabilities 12 month as first filed
2018-09-30$1.02M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06
$275.00K
derived: sum of 2 quarters · filed 2018-11-06
$1.34M
10-Q · filed 2018-11-06
$174.00K
derived: sum of 4 quarters · filed 2018-11-06
2018-06-30-$749.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07
$320.00K
10-Q · filed 2018-08-07
-$850.00K
derived: sum of 3 quarters · filed 2018-08-07
$951.00K
derived: sum of 4 quarters · filed 2018-11-06
2018-03-31$1.07M
10-Q · filed 2018-05-08
-$101.00K
derived: sum of 2 quarters · filed 2018-05-08
$1.70M
derived: sum of 3 quarters · filed 2018-11-06
$552.00K
derived: sum of 4 quarters · filed 2018-11-06
2017-12-31-$1.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
$631.00K
derived: sum of 2 quarters · filed 2018-11-06
-$517.00K
derived: sum of 3 quarters · filed 2018-11-06
$644.00K
10-K · filed 2018-02-27
2017-09-30$1.80M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06
$653.00K
derived: sum of 2 quarters · filed 2018-11-06
$1.81M
10-Q · filed 2018-11-06
$100.00K
derived: sum of 4 quarters · filed 2018-11-06
2017-06-30-$1.15M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07
$13.00K
10-Q · filed 2018-08-07
-$1.70M
derived: sum of 3 quarters · filed 2018-08-07
-$1.71M
derived: sum of 4 quarters · filed 2018-08-07
2017-03-31$1.16M
10-Q · filed 2018-05-08
-$553.00K
derived: sum of 2 quarters · filed 2018-05-08
-$557.00K
derived: sum of 3 quarters · filed 2018-05-08
$991.00K
derived: sum of 4 quarters · filed 2018-05-08
2016-12-31-$1.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
-$1.72M
derived: sum of 2 quarters · filed 2018-02-27
-$170.00K
derived: sum of 3 quarters · filed 2018-02-27
$940.00K
10-K · filed 2018-02-27
2016-09-30-$4.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02
$1.54M
derived: sum of 2 quarters · filed 2017-11-02
$2.65M
10-Q · filed 2017-11-02
$4.11M
10-Q · filed 2016-11-03
$773.00K
derived: sum of 4 quarters · filed 2018-02-27
2016-06-30$1.55M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03
$2.66M
10-Q · filed 2017-08-03
$3.32M
10-Q · filed 2016-08-04
$777.00K
derived: sum of 3 quarters · filed 2018-02-27
$2.35M
derived: sum of 4 quarters · filed 2018-02-27
2016-03-31$1.11M
10-Q · filed 2017-05-04
$3.96M
10-Q · filed 2016-05-05
-$771.00K
derived: sum of 2 quarters · filed 2018-02-27
$805.00K
derived: sum of 3 quarters · filed 2018-02-27
$200.00K
derived: sum of 4 quarters · filed 2018-02-27
2015-12-31-$1.88M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
-$305.00K
derived: sum of 2 quarters · filed 2018-02-27
-$910.00K
derived: sum of 3 quarters · filed 2018-02-27
$90.00K
10-K · filed 2018-02-27
$1.16M
10-K · filed 2016-02-23
2015-09-30$1.58M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03
$971.00K
derived: sum of 2 quarters · filed 2016-11-03
$1.97M
10-Q · filed 2016-11-03
$1.42M
10-Q · filed 2015-11-03
$1.34M
derived: sum of 4 quarters · filed 2017-03-02
2015-06-30-$605.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04
$395.00K
10-Q · filed 2016-08-04
$175.00K
10-Q · filed 2015-08-04
-$235.00K
derived: sum of 3 quarters · filed 2017-03-02
$513.00K
derived: sum of 4 quarters · filed 2017-03-02
2015-03-31$1.00M
10-Q · filed 2016-05-05
$370.00K
derived: sum of 2 quarters · filed 2017-03-02
$1.12M
derived: sum of 3 quarters · filed 2017-03-02
$1.26M
derived: sum of 4 quarters · filed 2017-03-02
2014-12-31-$630.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02
$118.00K
derived: sum of 2 quarters · filed 2017-03-02
$261.00K
derived: sum of 3 quarters · filed 2017-03-02
$240.00K
10-K · filed 2017-03-02
$1.65M
10-K · filed 2015-02-23
2014-09-30$748.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03
$891.00K
derived: sum of 2 quarters · filed 2015-11-03
$870.00K
10-Q · filed 2015-11-03
$2.98M
10-Q · filed 2014-11-10
$1.19M
derived: sum of 4 quarters · filed 2016-02-23
2014-06-30$143.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04
$122.00K
10-Q · filed 2015-08-04
-$12.00K
10-Q · filed 2014-08-07
$437.00K
derived: sum of 3 quarters · filed 2016-02-23
$658.00K
derived: sum of 4 quarters · filed 2016-02-23
2014-03-31-$21.00K
10-Q · filed 2015-05-05
-$209.00K
10-Q · filed 2014-05-12
$294.00K
derived: sum of 2 quarters · filed 2016-02-23
$515.00K
derived: sum of 3 quarters · filed 2016-02-23
$51.00K
derived: sum of 4 quarters · filed 2016-02-23
2013-12-31$315.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23
$536.00K
derived: sum of 2 quarters · filed 2016-02-23
$72.00K
derived: sum of 3 quarters · filed 2016-02-23
-$67.00K
10-K · filed 2016-02-23
$25.00K
10-K · filed 2014-02-28
2013-09-30$221.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10
-$243.00K
derived: sum of 2 quarters · filed 2014-11-10
-$382.00K
10-Q · filed 2014-11-10
-$382.86K
10-Q · filed 2013-11-07
-$365.27K
derived: sum of 4 quarters · filed 2014-11-10
2013-06-30-$464.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
-$603.00K
10-Q · filed 2014-08-07
-$599.39K
10-Q · filed 2013-08-09
-$586.27K
derived: sum of 3 quarters · filed 2014-08-07
-$225.07K
derived: sum of 4 quarters · filed 2014-08-07
2013-03-31-$139.00K
10-Q · filed 2014-05-12
-$122.27K
derived: sum of 2 quarters · filed 2014-05-12
$238.93K
derived: sum of 3 quarters · filed 2014-05-12
2012-12-31$16.73K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28
$377.93K
derived: sum of 2 quarters · filed 2014-02-28
$205.00K
10-K · filed 2014-02-28
2012-09-30$361.20K
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07
$188.27K
10-Q · filed 2013-11-07
2012-06-30-$172.93K
10-Q · filed 2013-08-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
COMPASS Pathways plc (CMPS)$1.812B-4.87
Septerna, Inc. (SEPN)United States$1.783B-63.01
Xencor Inc (XNCR)United States$1.776B-7.33
Zymeworks Inc. (ZYME)United States$1.902B-12.44
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74
Sarepta Therapeutics, Inc. (SRPT)United States$1.941B-13.89
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Biohaven Ltd. (BHVN)United States$1.990B-3.83